Showing 81 - 100 results of 2,112 for search '(( significantly ((better decrease) OR (teer decrease)) ) OR ( significantly less decrease ))', query time: 0.31s Refine Results
  1. 81
  2. 82
  3. 83
  4. 84
  5. 85
  6. 86
  7. 87
  8. 88
  9. 89
  10. 90
  11. 91

    Key Resources. by Jeffrey Chin (22538086)

    Published 2025
    “…Unexpectedly, we found that Tax1bp1-deficient mice were less susceptible to <i>Mtb</i> infection, and generated reduced inflammatory cytokine responses, compared to wild-type mice; the same mutant mice exhibited decreased growth of, and inflammatory cytokine responses to, <i>Listeria monocytogenes</i>, suggesting that Tax1bp1 plays a role in host responses to multiple intracellular pathogens. …”
  12. 92

    Tax1bp1-deficiency reduces autophagy flux. by Jeffrey Chin (22538086)

    Published 2025
    “…Unexpectedly, we found that Tax1bp1-deficient mice were less susceptible to <i>Mtb</i> infection, and generated reduced inflammatory cytokine responses, compared to wild-type mice; the same mutant mice exhibited decreased growth of, and inflammatory cytokine responses to, <i>Listeria monocytogenes</i>, suggesting that Tax1bp1 plays a role in host responses to multiple intracellular pathogens. …”
  13. 93
  14. 94

    Study data. by Jie Liu (15128)

    Published 2025
    “…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…”
  15. 95

    Summary of clinical outcomes after 9 months. by Jie Liu (15128)

    Published 2025
    “…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…”
  16. 96

    Approval by the research ethics committee. by Jie Liu (15128)

    Published 2025
    “…</p><p> Conclusion </p><p>During the COVID-19 pandemic, both roxadustat and ESAs effectively improved renal anemia in PD patients, however, the roxadustat group experienced less additional costs for anemia correction and better medication compliance.…”
  17. 97
  18. 98
  19. 99
  20. 100